)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
EXACT Therapeutics
EXACT Therapeutics (EXTX) investor relations material
EXACT Therapeutics has been delisted
EXACT Therapeutics H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary3 Sep, 2026
Executive summary
Advanced the Phase 2 ENACT trial for PS101 in pancreatic cancer, completing two positive safety reviews and enabling unrestricted enrolment at the higher 60 μl/kg dose.
Early clinical data showed substantial reductions in tumour marker CA 19-9 and encouraging radiological responses, with one patient achieving complete surgical resection.
Raised NOK 59.4 million through warrant exercises, strengthening the financial position.
Approved delisting from Euronext Growth Oslo, with last trading day set for 9 October 2026.
Financial highlights
Net loss for H1 2026 was NOK -38.0 million, improved from NOK -49.2 million in H1 2025.
Total operating expenses decreased to NOK 38.0 million from NOK 45.8 million year-over-year.
Payroll and related expenses were NOK 11.7 million, down from NOK 16.1 million in H1 2025.
Free cash and cash equivalents at 30 June 2026 were NOK 49.1 million, up from NOK 24.4 million at year-end 2025.
Total assets increased to NOK 85 million from NOK 67.4 million at year-end 2025.
Outlook and guidance
Focus remains on patient enrolment and execution of the ENACT Phase 2 trial at 60 μl/kg.
Interim efficacy analysis expected around end of 2026; final analysis planned for H1 2027.
Exploring future opportunities for PS101 in combination with RAS-targeted therapies.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from EXACT Therapeutics
- ACT clinical progress advances, but ENACT and ongoing operations depend on new financing.EXTX
H2 2023 - Delisting aims to unlock VC funding and reduce costs as clinical progress accelerates.EXTXStatus update
- ENACT Phase 2 trial advanced, R&D costs rose, and liquidity secured via warrant exercise.EXTXH2 2025
- Strong early clinical results and secured funding support expansion in oncology and beyond.EXTXInvestor update
- Ultrasound-activated therapy achieved >10x tumor reduction and advances to Phase 2 in pancreatic cancer.EXTXISTU 2024 presentation
- ACT delivers >10x tumor shrinkage in liver metastases and advances to Phase 2 pancreatic cancer trials.EXTXCMR Symposium 2024 presentation
- $13M raised, including $7M from a medtech leader, to fund phase II trial and expand ACT platform.EXTXStatus update
- PS101 delivers promising early results in pancreatic cancer, with strong clinical and financial momentum.EXTXCompany presentation
- ACT technology shows strong clinical promise in oncology, with Phase 2 trials underway.EXTXDNB Carnegie Nordic Healthcare Conference Presentation
EXACT Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
EXACT Therapeutics AS is a clinical-stage biopharmaceutical company headquartered in Oslo, Norway. The company is pioneering a novel ultrasound-mediated technology platform called Acoustic Cluster Therapy (ACT). This approach aims to significantly enhance the clinical utility of a wide range of therapeutic agents for a variety of applications, including oncology (both chemotherapy and immunotherapy), neurological conditions, and gene therapy. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.